PDCD1 and malignant colon neoplasm: Moreover, anti-SIRPα antibody treatment increased NK cell and CD8+ T-cell infiltration and, when combined with anti-PD-1, yielded a more potent anti-tumour effect in mouse models of colon cancer [137].